Consequences of COVID 19 Pandemic on Childhood Asthma (VIRASTHCOVID)

May 11, 2026 updated by: University Hospital, Lille

Consequences of SARS-CoV2 Pandemic on Childhood Asthma Control and Exacerbations: French Multicenter Cross-sectional VIRASTHMA COVID G4 Study

The SARS-CoV2 pandemic, which emerged in the first quarter of 2020, has led to an unprecedented health crisis in our modern healthcare systems and has resulted in strong national public health measures. The impact of the pandemic and its indirect environmental consequences on pediatric asthma is currently being assessed. In particular, the study of its role on the risk of exacerbations and modification of control is one of the priority research objectives defined by European societies.

The primary aim is to study the impact of the pandemic on asthma control in children aged 3-16 years with a medical diagnosis of asthma, compared to data from other observational cohorts conducted in the same region prior to the pandemic.

A sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.

Study Overview

Status

Completed

Conditions

Detailed Description

Children aged 3-16 years with a medical diagnosis of asthma, will be assessed for asthma control, exacerbation rate.

Data will be compared to data from other observational cohorts conducted in the same region prior to the pandemic.

A sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.

Study Type

Observational

Enrollment (Actual)

577

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lille, France
        • CHU Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 16 years (Child)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

children and adolescents diagnosed with asthma.

Description

Inclusion Criteria:

  • Children and adolescents aged 3 to 16 years old
  • With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months,
  • Assessed in one of the pediatric departments participating in the study,
  • After written consent of at least one of the 2 parents and/or representative of the parental authority, and of the child if he is older than 8 years old.

Criteria for the sub-population assessed at "exacerbation" and second visit:

  • Children and adolescents aged 3 to 16 years
  • With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months,
  • Hospitalized for a severe asthma exacerbation (requiring hospitalization and general corticosteroid therapy) at Lille University Hospital
  • After written consent of both parents and/or representative of the parental authority, and of the child if he is over 8 years old

Exclusion Criteria:

  • History of chronic respiratory disease other than asthma,
  • Inability of parents to receive informed information, inability to participate in the entire study, refusal to sign the consent form

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Group 1
population included in the VIRASTHMA COVID G4 study
Group 2
population included in the previous studies "VIRASTHMA", "CHAMPIASTHMA" (IRDCB No.: 2019-A03310-57), "COBRAPED" (NCT02114034), "VIRASTHMA 2" (IRDCB No.: 2014 A01687 40, NCT: 03960359), "INCOVPED" (pediatric emergencies, NCT04336761).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Controlled asthma
Time Frame: at inclusion
Composite criteria defined by a cACT (4-11 years) or ACT (12-16 years) score ≥ 20 and according to GINA criteria.
at inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characteristics of asthma
Time Frame: At inclusion and follow-up visit at 2-4 months for the sub-population included at exacerbation
Composite criteria : allergic phenotype, severity assessed by GINA treatment level, number of exacerbations in the past year, lung function
At inclusion and follow-up visit at 2-4 months for the sub-population included at exacerbation
history of SARS-Cov2 infection in the past year
Time Frame: At inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
history of SARS-Cov2 infection based on patient report
At inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
number of infectious episodes in the past year
Time Frame: At inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
number of infectious episodes based on patient report
At inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
Observance
Time Frame: At Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
Assessed by four-items Morisky-Green questionnaire : 1/ Do you ever forget to take your medication; 2/ Are you careless sometimes about taking your medication 3/ When you feel better, do you sometimes stop taking your medication 4/ Sometimes, if you feel worse when you take your medication, do you stop taking it. An answer "no" to any of the 4 questions is considered as "not well-observed medication".
At Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
QoL (Quality of life) in children aged 7-17 years
Time Frame: At Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation

Assessed by PAQLQ : PAEDIATRIC ASTHMA QUALITY OF LIFE QUESTIONNAIRE. The PAQLQ has 23 questions in 3 domains (symptoms, activity limitation and emotional function). The activity domain contains 3 'patient-specific' questions. Children are asked to think about how they have been during the previous week and to respond to each of the 32 questions on a 7-point scale (7 = not bothered at all -

1 = extremely bothered). The overall PAQLQ score is the mean of all 23 responses and the individual domain scores are the means of the items in those domains. The highest the score is, the better QoL is.

At Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
Outdoor levels of pollutants and pollens
Time Frame: At Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
Composite criteria : monthly average measurements of CO, O3, NO, NO2, SO2, PM2.5, PM10 and pollen counts
At Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbation
Respiratory virus infection (SARS-CoV2 and other)
Time Frame: at exacerbation and at follow-up visit at 2-4 months for the sub-population included at exacerbation
Results of viral PCR
at exacerbation and at follow-up visit at 2-4 months for the sub-population included at exacerbation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stéphanie Lejeune, MD, University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 14, 2021

Primary Completion (Actual)

March 31, 2025

Study Completion (Actual)

March 31, 2025

Study Registration Dates

First Submitted

March 29, 2021

First Submitted That Met QC Criteria

March 29, 2021

First Posted (Actual)

March 30, 2021

Study Record Updates

Last Update Posted (Actual)

May 14, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

March 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe